This article describes the survival after childhood acute leukemia (AL) and non- 
Introduction
In France, as is the case in other industrialized countries, acute leukemia (AL) is the most frequent cancer in children aged less than 15 years (1). Acute lymphoblastic leukemia (ALL) accounts for approximately 80% of childhood leukemia cases. The incidence rate for ALL, standardized on the world population, is 34.3 cases per million children per year with a sex ratio of 1.4 in mainland France (2) . Acute myeloid leukemia (AML) and non-Hodgkin's lymphoma (NHL) are rarer childhood diseases, with a standardized rate of 7.1 and 8.9 cases per million children per year, respectively.
Over the past 30 years, a remarkable increase in the childhood survival after malignant hematopoietic diseases has been observed in industrialized countries.
Non-Hodgkin's lymphoma, which was a fatal cancer before 1970, has become a curable disease in the great majority of cases. In spite of an improvement in the survival of children with acute non-lymphocytic leukemia, survival at 5 years still remained very low in Europe with a rate of 37% (3) at the beginning of nineties.
Survival after ALL increased from 50% in the seventies to more than 80% in the nineties (4) . This improvement is particularly due to progress in the treatment networks and application of the advances in centres specializing in the treatment of childhood cancers (5).
The aim of this study was to describe the survival of children aged less than 15 years presenting with acute leukemia or non-Hodgkin's lymphoma and residing in mainland France at the time of diagnosis for the period from 1990 to 2000. This is the first French report on the survival of children with acute leukemia or NHL based on a nationwide basis. The data were provided by the French National Registry of Childhood Leukemia and Lymphoma (NRCL).
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Patients and method
* Case registration
The methods used by the NRCL to record cases and code diagnoses have been described in detail elsewhere (2) . The NRCL includes all malignant hematopoietic diseases occurring in children aged less than 15 years residing in mainland France at the time of diagnosis. However, Hodgkin's disease has only been recorded since 
* Statistical analysis
The observed survival rates were estimated using the Kaplan-Meier method. The roles of age at diagnosis (< 1 year, 1-4 years, 5-9 years and 10-14 years), gender, immunology for ALL, histology for NHL, FAB (French American British) type for AML, inclusion in clinical trials and period of diagnosis were analyzed. The log rank test was used to compare the survival curves of the subgroups. Survival rates have been reported with their 95% confidence intervals in brackets. Multivariate analyses were carried out using a Cox proportional hazard model and the effects of the different variables on survival were estimated by hazard ratios (HR) for those covariates. In
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order to check the proportionality assumption of the Cox model, cumulative hazard functions [log (-log S (T))] were plotted.
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Results
* Population description
From 1990 to 2000, the NRCL registered 4876 cases of acute leukemia (3995 ALL, 812 AML and 69 unspecified AL) and 1137 cases of NHL as primary cancers. Table 1 shows the distribution of cases by disease type. For ALL, 57% of the cases were boys and 48% aged 1-4 years, with the expected incidence peak at 2 years. AML was as frequent in girls as in boys. For NHL, the male/female ratio was 2. Out of the 1137 NHL cases, 64% had B-cell NHL, of which Burkitt's lymphoma was the most frequent histological sub-type (72%). Lymphoblastic T-cell NHL accounted for 77% of the T-cell NHL cases.
The survival rates for ALL were 94% (93-95) at 1 year and 82% (80-83) at 5 years ( Fig. 1 ). Deaths occurred regularly over the period. During the 5 years of follow-up, the survival of AML cases was consistently lower than that of ALL cases.
The AML survival rate decreased markedly over the 3 years post-diagnosis, from 93% (91-95) at 3 months to 60% (57-64) at 3 years. Death due to NHL mainly occurred in the two years post-diagnosis (125 deaths at 2 years). Table 2 shows the distribution of leukemia and lymphoma cases and their survival rates. Acute leukemia of the M4/5 and M1/2 types was the most frequent, accounting for 36 and 30% of AML cases, respectively. The acute promyelocytic (M3) and myeloblastic (M1-M2) types had the best prognoses at 5 years, with survival rates of 83% (73-93) and 62% (56-68), respectively. Acute megakaryoblastic leukemia (M7)
* Diagnostic subtypes
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(38% (28-49)) and erythroleukemia M6 (41% (19-64)) had the poorest outcomes.
Immature B-cell ALL accounted for 95% of B-cell ALL. The survival rate at 5 years (85% (84-86)) was higher than that for T-cell ALL (67% (63-71) ). There were also survival differences between the histological types of NHL. Five-year survival was markedly greater for Burkitt NHL (92% (90-94) ) than for T-cell lymphoblastic NHL (79% (73-84) ). Table 3 shows the survival rates at 3 months, 1 year and 5 years for AL and NHL by age at diagnosis, gender and presence/absence of Down's syndrome. Irrespective of follow-up duration, the survival of infants aged less than 1 year was consistently inferior to that of children aged 1-9 years. The 5-year survival of infants aged less than 1 year was 48% for ALL and 45% for AML, while that for children aged 1-4 years was 87% for ALL and 62% for AML. In contrast, the survival of children aged 1-4 years with T-cell ALL was the same survival as those of the other age groups (67%, 63%, 72%, 62% for less than 1 year, 1-4, 5-9 and more than 10 years). For NHL, no major variation with age was observed. There was no significant betweengender difference in survival irrespective of follow-up duration or disease subtype.
* Cases individual characteristics
The prognosis was poorest in ALL cases with Down's syndrome, but Down's syndrome did not significantly decrease the survival of the AML cases.
Multivariate analyses gave similar results (table 4). The variables included in the model were gender, age, presence of Down's syndrome, period of diagnosis, and FAB type for AML. For ALL, infants aged less than 1 year had a six-fold higher risk of death than children aged 1-4 years (HR = 5.7 (5.4-6.0)). The AML hazard ratio was also significantly higher for infants (HR = 1.7 (1.4-2.0)) and for cases aged more than
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10 years (HR = 1.3 (1.0-1.6)) than for those aged 1-4 years. No significant variation in hazard ratio with age was observed for T-cell or mature B-cell ALL.
* Inclusion in clinical trial protocols
Almost all the ALL (94%) and most of the NHL cases (81%) were enrolled in clinical trials between 1990 and 2000 ( Table 1 ). Children with AML were less often (66%) included in trials. The children were enrolled in a clinical trial or reported as trial exclusions, or not included in a trial but nonetheless treated per-protocol. In the latter situation, non-inclusion was considered related to reasons other than clinical or laboratory criteria (e.g. parent's refusal). The survival of the cases included in a trial was not different to that of cases not included but treated per-protocol.
* Temporal trend
From the first (1990) (1991) (1992) to the last (1997-2000) diagnostic period, 5-year survival increased from 77% (75 -80) to 85% (83 -87) for ALL and from 47% (41 -54) to 61% (55 -67) for AML. In contrast to the survival rate for Burkitt ALL cases, which was already high in the early nineties, the survival of children with immature B-cell and T-cell ALL improved over the period, increasing from 80% to 88% and from 60% to 71%, respectively. The temporal increase in AL survival was remained in the multivariate analysis (Table 4 
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Discussion
This study was the first to analyze childhood AL and NHL survival in France on a nation-wide basis. The strength of the study resides in the high proportion of cases with microscopic diagnosis and complete follow-up, and in the exhaustiveness of the NRCL (99% for leukemia and 97% for NHL). The authors previously reported (2) that the characteristics of the French cases (sex-ratio, age distribution, presence/absence of Down's syndrome) were similar to those of other European cases. The present study did not address white blood cell count, a known prognostic factor for ALL (6, 7, 8) that is used in risk assessment, since that variable is not recorded in the NRCL.
Survival estimations and temporal variations
Overall, survival improved over the whole period, 1990-2000. These positive trends reflect therapeutic progress: combination chemotherapies, large scale use of bonemarrow transplants for AML and adaptation of treatment intensity to the severity of the disease (9, 10) . Several European cancer registries have reported this temporal survival trend for periods before (3, (11) (12) (13) or during (6) that considered herein. In the United States, SEER noted a similar increase in survival for AL (14) . Between 1970 and 1990, the prognosis of NHL improved in Europe (15) and the United States (14) , as treatments took into account disease staging and histological subtype (16, 17) .
Following that marked increase, the 5-year survival after NHL seems to have (6, 18) and by recent large-scale European clinical trials (7, 19, 20, 21) .
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For AML, contrasting survivals were observed, with the highest rate for subtype M3 and the lowest for subtype M7, as has been reported in previous studies (3, 22) .
Gender
In the present data, gender did not affect AL survival. For ALL, this finding is not consistent with previous studies (12, 18, 23) that reported a more positive outcome for girls. Some authors have suggested that the difference was partially explained by the differences in the distributions of immunophenotype and DNA index or by different biological mechanisms of reaction to treatment, depending on gender. With regard to AML, the result reported herein is consistent with several studies (11, 24, 25) . Two other studies have reported superior survival for girls, but no biological mechanism has been suggested as an explanation (3, 26) .
Infants
The poor survival of infant AL cases aged less than 1 year is consistent with most cancer registry studies (3, 12, 6, 18) and clinical trials (7) . In line with Pullen et al. (27) , this study did not evidence any between-age-group difference in T-cell ALL survival. For AML, a marked increase in the survival of infants aged less than one year was observed throughout the period (90-95: 33% (21-44) vs. 95-00: 57% (46-69)). In the last period, infants had a prognosis that was as good as that of other children (p = 0.09). This improvement in survival has also been observed in clinical trial protocols: age less than one year was not an adverse prognostic factor in the LAME 89/91 (28) or AML10 and AML12 (20) trials.
Down's syndrome
As has been previously reported, survival was lower for children with ALL and Down's syndrome than for those without the syndrome, although survival tended to improve between 1990 and 2000. As Craze and Stiller (11, 29) have pointed out, in
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AML with Down's syndrome, the survival is similar to that observed in AML without the syndrome thanks to adaptation of chemotherapy to the patient's sensitivity (30) .
Cases per centre
The number of cases treated by hospital department did not influence survival. Stiller et al. reported similar results for children with ALL in the United Kingdom in the eighties (18) . In France, the homogeneity of survival is doubtless due to the fact that all cases are treated in specialized departments in which standardized patient care patterns are implemented irrespective of the number of cases treated.
The incidence and survival rates determined by the NRCL are similar to those reported by other European registry studies and clinical trials. For most AL, survival clearly increased over the period, 1990-2000.
